Symptom Interval and Patient Delay Affect Survival Outcomes in Adolescent Cancer Patients

被引:14
作者
Jin, Song Lee [1 ,2 ]
Hahn, Seung Min [1 ,2 ]
Kim, Hyo Sun [1 ,2 ]
Shin, Yoon Jung [1 ,2 ]
Kim, Sun Hee [1 ,2 ]
Lee, Yoon Sun [3 ]
Lyu, Chuhl Joo [1 ,2 ]
Han, Jung Woo [1 ,2 ]
机构
[1] Yonsei Univ, Yonsei Univ Hlth Syst, Coll Med, Div Pediat Hematol & Oncol,Dept Pediat, 50-1 Yonsei Ro, Seoul 03722, South Korea
[2] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Dept Pediat Hematooncol, Seoul, South Korea
[3] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Dept Pharm, Seoul, South Korea
关键词
Adolescent cancer patients; symptom interval; patient delay; SECONDARY SEXUAL CHARACTERISTICS; ACUTE LYMPHOBLASTIC-LEUKEMIA; OFFICE SETTINGS NETWORK; PEDIATRIC SOLID TUMORS; CHILDHOOD-CANCER; YOUNG-ADULTS; CLINICAL-TRIALS; CONTROL PROGRAM; BREAST-CANCER; EWING TUMORS;
D O I
10.3349/ymj.2016.57.3.572
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Unique features of adolescent cancer patients include cancer types, developmental stages, and psychosocial issues. In this study, we evaluated the relationship between diagnostic delay and survival to improve adolescent cancer care. Materials and Methods: A total of 592 patients aged 0-18 years with eight common cancers were grouped according to age (adolescents, >= 10 years; children, <10 years). We retrospectively reviewed their symptom intervals (SIs, between first symptom/sign of disease and diagnosis), patient delay (PD, between first symptom/sign of disease and first contact with a physician), patient delay proportion (PDP), and overall survival (OS). Results: Mean SI was significantly longer in adolescents than in children (66.4 days vs. 28.4 days; p<0.001), and OS rates were higher in patients with longer SIs (p=0.001). In children with long SIs, OS did not differ according to PDP (p=0.753). In adolescents with long SIs, OS was worse when PDP was >= 0.6 (67.2%) than <0.6 (95.5%, p=0.007). In a multivariate analysis, adolescents in the long SI/PDP >= 0.6 group tended to have a higher hazard ratio (HR, 6.483; p=0.069) than those in the long SI/PDP <0.6 group (HR=1, reference). Conclusion: Adolescents with a long SI/PDP >= 0.6 had lower survival rates than those with a short SI/all PDP or a long SI/PDP <0.6. They should be encouraged to seek prompt medical assistance by a physician or oncologist to lessen PDs.
引用
收藏
页码:572 / 579
页数:8
相关论文
共 43 条
[1]   Psychosocial issues in adolescents with cancer [J].
Abrams, Annah N. ;
Hazen, Eric P. ;
Penson, Richard T. .
CANCER TREATMENT REVIEWS, 2007, 33 (07) :622-630
[2]  
Albritton K., 2006, Closing the gap: research and care imperatives for adolescents and young adults with cancer
[3]   Access to care [J].
Albritton, Karen H. ;
Eden, Tim .
PEDIATRIC BLOOD & CANCER, 2008, 50 (05) :1094-1098
[4]   Time to Diagnosis of Ewing Tumors in Children and Adolescents Is Not Associated With Metastasis or Survival [J].
Alonso, Lorenzo ;
Navarro-Perez, Victor ;
Sanchez-Munoz, Alfonso ;
Alba, Emilio .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (35) :4020-U162
[5]   DELAY IN SEEKING A CANCER-DIAGNOSIS - DELAY STAGES AND PSYCHOPHYSIOLOGICAL COMPARISON PROCESSES [J].
ANDERSEN, BL ;
CACIOPPO, JT ;
ROBERTS, DC .
BRITISH JOURNAL OF SOCIAL PSYCHOLOGY, 1995, 34 :33-52
[6]   "Delays" in Diagnosis: A Misleading Concept, Yet Providing Opportunities for Advancing Clinical Care [J].
Barr, Ronald D. .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2014, 36 (03) :169-172
[7]   The distinctive biology of cancer in adolescents and young adults [J].
Bleyer, Archie ;
Barr, Ronald ;
Hayes-Lattin, Brandon ;
Thomas, David ;
Ellis, Chad ;
Anderson, Barry .
NATURE REVIEWS CANCER, 2008, 8 (04) :288-298
[8]  
Bleyer Archie, 2005, Curr Probl Pediatr Adolesc Health Care, V35, P182, DOI 10.1016/j.cppeds.2005.02.001
[9]   Adolescents and young adults with cancer - The scope of the problem and criticality of clinical trials [J].
Bleyer, Archie ;
Budd, Troy ;
Montello, Michael .
CANCER, 2006, 107 (07) :1645-1655
[10]   Cancer in older adolescents and young adults: Epidemiology, diagnosis, treatment, survival, and importance of clinical trials [J].
Bleyer, WA .
MEDICAL AND PEDIATRIC ONCOLOGY, 2002, 38 (01) :1-10